| Literature DB >> 24355711 |
Xiaomeng Wang1, Wenwen Yu1, Hui Li1, Jinpu Yu1, Xinwei Zhang1, Xiubao Ren1, Shui Cao2.
Abstract
Cytokine-induced killer (CIK) cells, which display both potent anti-tumor ability of T lymphocytes and non-major histocompatibility complex (MHC) restricted killing tumor cells capacity of natural killer (NK) cells are capable of recognizing and lysing a broad array of tumor targets. They have begun to be used in clinical care with good prospects for treatment success. CIK cells are a heterogeneous cell population that contain CD3(+)CD56(+) cells, CD3(-)CD56(+) natural killer (NK) cells and CD3(+)CD56(-) T cells on which much attention has been focused. This review will summarize the connections and differences among CD3(+)CD56(+)CIK cells, CD3(-)CD56(+) NK cells and CD3(+)CD56(-) T cells in the following aspects: the main cell surface molecule, killing mechanism, and clinical applications so that treatment with CIK cells can be optimized and further to enhance the antitumor effect.Entities:
Keywords: ADCC; APCs; CIK; Cytokine-induced killer (CIK) cells; Cytokine-induced killer cells; DC; Immunotherapy; KIR; Killer immunoglobulin-like receptors; LAK; NK; Natural killer (NK) cells; T cells; TIL; Tumor immunology; antibody-dependent cellular cytotoxicity; antigen presenting cells; dendritic cell; lymphokine activated killer cells; natural killer cells; tumor-infiltrating lymphocytes cells
Mesh：
Substances：
Year: 2013 PMID： 24355711 DOI： 10.1016/j.cellimm.2013.11.009
Source DB: PubMed Journal: Cell Immunol ISSN： 0008-8749 Impact factor: 4.868